Tyra Biosciences (TYRA) Free Cash Flow (2020 - 2026)
Tyra Biosciences' (TYRA) quarterly Free Cash Flow came in at -$32.7 million in Q1 2026, down 28.29% YoY from -$45.5 million in Q1 2025, and down 37.99% on a QoQ basis from -$23.7 million in Q4 2025.
Tyra Biosciences (TYRA) Free Cash Flow (2020 - 2026) Analysis & Trends
Tyra Biosciences (TYRA) has 7 years of Free Cash Flow data on file, last reported at -$32.7 million in Q1 2026.
- Quarterly Free Cash Flow fell 28.29% year-over-year to -$32.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$102.4 million (down 38.9% YoY) and the FY2025 annual result came in at -$95.2 million, down 35.17% from the prior year.
- Free Cash Flow slipped to -$32.7 million in Q1 2026, from -$23.7 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$9.2 million in Q1 2022 to a low of -$32.7 million in Q1 2026.
- A 5-year average of -$17.6 million and a median of -$17.3 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 274.6% — and 2023, when it soared 43.01%.
- Tracing TYRA's Free Cash Flow over 5 years: stood at -$12.0 million in 2022, then dropped by 18.08% to -$14.1 million in 2023, then slumped by 38.63% to -$19.6 million in 2024, then declined by 20.77% to -$23.7 million in 2025, then plunged by 37.99% to -$32.7 million in 2026.
- The last three Free Cash Flow figures came in at -$32.7 million (Q1 2026), -$23.7 million (Q4 2025), and -$22.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Tyra Biosciences | 1.51 Bn | 1.51 Bn | - | -31.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.14 Mn |
| Jun 30, 2026 | -31.14 Mn |
| Mar 31, 2026 | -32.66 Mn |
| Mar 31, 2026 | -32.66 Mn |
| Dec 31, 2025 | -23.67 Mn |
| Dec 31, 2025 | -23.67 Mn |
| Sep 30, 2025 | -22.36 Mn |
| Sep 30, 2025 | -22.36 Mn |
| Jun 30, 2025 | -23.73 Mn |
| Jun 30, 2025 | -23.73 Mn |
| Mar 31, 2025 | -25.46 Mn |
| Mar 31, 2025 | -25.46 Mn |
| Dec 31, 2024 | -19.60 Mn |
| Dec 31, 2024 | -19.60 Mn |
| Sep 30, 2024 | -18.52 Mn |
| Sep 30, 2024 | -18.52 Mn |
| Jun 30, 2024 | -10.16 Mn |
| Jun 30, 2024 | -10.16 Mn |
| Mar 31, 2024 | -22.16 Mn |
| Mar 31, 2024 | -22.16 Mn |